Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
ARS Pharmaceuticals, Inc. (SPRY) had Cash Flow from Financial Activities of $3.42M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$15.72M |
|
$-44.88M |
|
$4.98M |
|
$10.73M |
|
$63.33M |
|
$-47.61M |
|
$2.73M |
|
$-44.88M |
|
$-44.88M |
|
$-44.88M |
|
$-44.88M |
|
$-44.88M |
|
$-44.88M |
|
$-47.61M |
|
$-48.80M |
|
98.36M |
|
98.36M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$281.44M |
|
$1.07M |
|
$32.04M |
|
$313.47M |
|
$45.60M |
|
$71.96M |
|
$75.55M |
|
$121.15M |
|
$192.32M |
|
$179.35M |
|
$192.32M |
|
98.70M |
|
| Cash Flow Statement Financials | |
$-80.33M |
|
$77.64M |
|
|
Cash Flow from Financial Activities |
$3.42M |
$50.82M |
|
$51.54M |
|
$0.72M |
|
$10.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.17 |
|
-- |
|
-- |
|
0.27 |
|
0.37 |
|
68.29% |
|
-302.95% |
|
-302.95% |
|
-- |
|
-285.57% |
|
-285.57% |
|
$-80.48M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
0.57 |
|
0.63 |
|
143.88 |
|
-23.34% |
|
-25.03% |
|
-14.32% |
|
-16.98% |
|
$1.95 |
|
$-0.82 |
|
$-0.82 |
|